‘No Simple Formula’: US FDA Decisions On Surrogate Endpoints Are Complex, Case-Specific

 
• By Sue Sutter
  
Math formulas
The FDA has no simple formula for determining whether a surrogate endpoint is reasonably likely to predict clinical benefit. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards